Sildenafil dose proportionality describes how systemic exposure changes when the administered dose changes. Current U.S. sildenafil labeling states that sildenafil pharmacokinetics are dose-proportional over the recommended dose range, meaning that exposure generally scales predictably across the labeled erectile-dysfunction dose range under comparable conditions.
The research evidence adds an important boundary to that statement. In a single-dose pharmacokinetic study of 25, 50, 100 and 200 mg in healthy men, exposure increased slightly more than proportionally across the wider 25–200 mg range: a doubling of dose was predicted to increase Cmax by about 2.2-fold and AUC by about 2.1-fold.
This page explains how those findings fit together. Dose proportionality is an empirical relationship tied to a particular range, population and study design; it does not mean that exposure must scale perfectly at every dose, and it does not provide a method for choosing an individual dose. Clinical regimen information remains on the sildenafil dosage page.
Dose proportionality asks whether a change in administered sildenafil dose produces approximately the same proportional change in an exposure metric. If dose doubles and AUC or Cmax also approximately doubles under otherwise comparable conditions, that metric is behaving dose-proportionally across the evaluated range.
For current ED sildenafil labeling, pharmacokinetics are described as dose-proportional over the recommended dose range. That range includes the labeled 25 mg, 50 mg and 100 mg dose levels rather than implying unlimited proportionality at progressively higher doses.
The range qualification is essential. Research extending sildenafil to 200 mg found a small greater-than-proportional increase in exposure, illustrating why proportionality should always be stated together with the dose interval over which it was evaluated. Within the broader sildenafil pharmacokinetic framework, this is a dose–exposure relationship rather than a dosing recommendation.
| Relationship | Conceptual Interpretation |
|---|---|
| Dose-proportional | A twofold dose increase produces approximately a twofold increase in exposure. |
| Greater than proportional | Exposure increases by more than the proportional dose change. |
| Less than proportional | Exposure increases by less than the proportional dose change. |
| Sildenafil labeling context | PK is described as dose-proportional over the recommended dose range. |
Administered dose is the starting input into the pharmacokinetic system, but the resulting plasma exposure depends on what happens after administration. Oral absorption and bioavailability determine systemic input, while distribution, metabolism and clearance shape the concentration-time profile after drug reaches circulation.
Under approximately linear conditions, increasing sildenafil dose while these other determinants remain sufficiently stable should produce a corresponding increase in AUC and Cmax. Dose proportionality is therefore evidence that the net PK system behaves predictably across the particular range studied.
A change in exposure with dose does not by itself identify which PK mechanism is responsible. The broader determinants of circulating sildenafil concentration are integrated on the sildenafil exposure page.
| PK Component | Role in Dose–Exposure Interpretation |
|---|---|
| Administered dose | Defines the nominal amount of drug input. |
| Bioavailability | Determines the fraction reaching systemic circulation unchanged. |
| Distribution | Shapes the relationship between circulating concentration and distributed drug. |
| Metabolism and clearance | Determine how efficiently parent sildenafil is removed. |
| AUC and Cmax | Show the resulting integrated and peak exposure. |
AUC is a central measure in dose-proportionality analysis because it integrates sildenafil concentration across time. Researchers can compare AUC at several dose levels and determine whether total systemic exposure changes approximately in direct proportion to dose.
In the published single-dose study that included 25, 50, 100 and 200 mg, sildenafil AUC showed a small greater-than-proportional relationship across the full range. The fitted relationship predicted an approximately 2.1-fold AUC increase for each twofold increase in dose rather than an exact 2.0-fold increase.
That small deviation does not contradict the current label statement that sildenafil PK is dose-proportional over the recommended range. The extended study included 200 mg, which lies above the current maximum recommended ED dose. Detailed interpretation of AUC itself remains on the sildenafil AUC page.
| AUC Observation | Interpretation |
|---|---|
| Exact proportional example | Twofold dose increase produces approximately twofold AUC. |
| 25–100 mg sildenafil context | Population PK evidence supports dose proportionality across this range. |
| 25–200 mg single-dose study | AUC increased slightly more than proportionally. |
| Estimated effect of doubling dose in that study | Approximately 2.1-fold increase in AUC. |
Cmax provides the complementary peak-exposure view of dose proportionality. Instead of integrating the entire concentration-time profile, it compares the highest observed sildenafil concentration reached after each studied dose.
In the 25–200 mg single-dose study, Cmax also increased slightly more than proportionally. A twofold increase in dose was predicted to produce approximately a 2.2-fold increase in Cmax.
Cmax is particularly sensitive to absorption rate, so its scaling can differ from AUC even within the same study. Peak-concentration interpretation remains on the sildenafil Cmax page, while this page focuses on how the metric changes across dose levels.
| Metric | Dose–Exposure Question |
|---|---|
| AUC | Does integrated exposure scale with dose? |
| Cmax | Does maximum observed concentration scale with dose? |
| Tmax | Does peak timing change as dose changes? |
| 25–200 mg study Cmax relationship | Approximately 2.2-fold increase for a doubling of dose. |
AUC and Cmax measure different properties of the sildenafil concentration-time profile, so exact equality in their dose relationships should not be expected. AUC reflects integrated exposure, whereas Cmax is affected more visibly by how rapidly systemic concentrations rise.
The sildenafil 25–200 mg study demonstrates this distinction quantitatively. For a twofold increase in dose, the fitted relationship predicted approximately 2.1-fold greater AUC but approximately 2.2-fold greater Cmax.
Both deviations were small, but the different values show why each exposure measure should be tested separately instead of labeling the entire PK profile proportional based on one parameter alone.
| Feature | AUC | Cmax |
|---|---|---|
| Represents | Integrated systemic exposure | Peak observed concentration |
| Uses the entire profile? | Yes | No |
| 25–200 mg doubling estimate | Approximately 2.1-fold | Approximately 2.2-fold |
| Can have a different dose relationship? | Yes | Yes |
Dose proportionality and linear pharmacokinetics are closely related but not perfect synonyms. Dose proportionality is an empirical observation that exposure scales with administered dose over a defined interval; linear PK is the broader concept that relevant input and removal processes behave consistently enough to produce predictable scaling.
Current sildenafil labeling summarizes the clinically relevant finding by stating that pharmacokinetics are dose-proportional over the recommended dose range. Population pharmacokinetic analysis has likewise reported proportional behavior over 25–100 mg.
The wider 25–200 mg single-dose study illustrates why the range must be specified: statistically significant nonproportionality could be detected when the supratherapeutic 200 mg level was included, although the size of the departure from exact proportionality was small.
| Concept | Sildenafil Interpretation |
|---|---|
| Dose proportionality | Exposure scales approximately with dose over a specified range. |
| Recommended ED dose range | Current labeling describes sildenafil PK as dose-proportional within this range. |
| Extended 25–200 mg research range | Small greater-than-proportional exposure was detected. |
| Linear PK | Broader description of stable dose-to-exposure behavior. |
Dose proportionality can break down when the relationship among dose, systemic input and elimination changes as dose increases. Potential mechanisms include dose-dependent bioavailability, saturation of presystemic processes or changes in clearance.
A departure from proportionality does not identify its mechanism automatically. If AUC increases slightly more than dose, for example, the data alone do not establish whether the cause is higher fractional systemic input, lower effective clearance or another process.
For sildenafil, the small greater-than-proportional pattern across 25–200 mg should therefore be reported as an observed PK relationship rather than attributed to a specific saturation mechanism without additional evidence.
| Potential PK Change | Possible Exposure Pattern |
|---|---|
| Fractional systemic availability increases | Greater-than-proportional AUC can occur. |
| Removal efficiency decreases | Greater-than-proportional exposure can occur. |
| Fractional systemic input decreases | Less-than-proportional exposure can occur. |
| Absorption rate changes | Cmax can deviate differently from AUC. |
For oral sildenafil, AUC reflects both administered dose and the fraction reaching systemic circulation. If absolute or relative bioavailability remains broadly stable across doses, exposure is more likely to scale in direct proportion to dose.
Population pharmacokinetic analysis reported dose-proportional sildenafil PK over 25–100 mg but evidence of approximately 40% higher relative bioavailability at 200 mg compared with the lower dose levels. That observation provides one possible PK context for why the expanded 25–200 mg range does not behave exactly proportionally.
The finding should not be generalized into a universal bioavailability value for every high-dose condition. Absolute sildenafil bioavailability and its interpretation remain on the sildenafil bioavailability page.
| Bioavailability Context | Dose–Exposure Interpretation |
|---|---|
| Stable fractional availability | Supports approximately proportional oral exposure. |
| 25–100 mg population PK | Dose-proportional behavior reported. |
| 200 mg population PK observation | Relative bioavailability was approximately 40% higher than at the lower doses. |
Clearance determines how efficiently parent sildenafil is removed from systemic circulation and is therefore one of the main determinants of the dose–AUC relationship. If clearance remains approximately constant while systemic input scales with dose, AUC can scale proportionally.
If clearance changes as exposure increases, the amount of AUC produced per unit dose can also change. This is one reason dose-normalized exposure is useful when examining possible nonlinearity.
The sildenafil data do not justify assuming that clearance saturation alone explains the small greater-than-proportional behavior at 200 mg. The quantitative removal-efficiency concept remains on the sildenafil clearance page.
| Clearance Behavior | Potential Exposure Relationship |
|---|---|
| Approximately constant | Supports proportional AUC when systemic input also scales proportionally. |
| Decreases as dose rises | Can contribute to greater-than-proportional AUC. |
| Increases as dose rises | Can contribute to less-than-proportional AUC. |
| Unknown mechanism | Observed nonproportionality should not be assigned to clearance without supporting evidence. |
Sildenafil is eliminated predominantly through hepatic metabolism, mainly through CYP3A4 with a smaller CYP2C9 contribution. Stable metabolic capacity across a dose range supports predictable clearance and therefore approximately proportional exposure.
If metabolic capacity became dose-dependent, parent-drug AUC could depart from proportional scaling. However, detecting a greater-than-proportional AUC pattern does not by itself demonstrate saturation of CYP3A4 or another specific metabolic pathway.
For the 25–200 mg research findings, the appropriate conclusion is that a small deviation from proportionality was observed across the expanded range. Detailed enzyme and metabolite mechanisms remain on the sildenafil metabolism page.
Dose proportionality can be visualized by comparing sildenafil concentration-time curves after different administered amounts. In a dedicated study, healthy male subjects received single oral doses of 25, 50, 100 and 200 mg, allowing the resulting profiles to be compared directly within the same crossover design.
As dose increased, the concentration-time curves rose to progressively greater concentrations and produced larger areas under the curve. The profiles therefore showed the expected directional increase in exposure even though statistical analysis identified a small greater-than-proportional component over the complete 25–200 mg range.
Visual comparison alone is not sufficient to establish proportionality because relatively small deviations can be difficult to judge from plotted curves. The mechanics of interpreting the profiles themselves are covered on the sildenafil concentration-time page.
| Curve Feature | What to Compare Across Doses |
|---|---|
| Peak height | Cmax scaling. |
| Area under the profile | AUC scaling. |
| Peak location | Whether Tmax changes systematically. |
| Dose-normalized shape | Whether exposure per unit dose remains broadly comparable. |
| Late decline | Whether disposition appears to change across doses. |
Dose normalization removes the expected arithmetic effect of administering a larger amount. AUC divided by dose and Cmax divided by dose can therefore be compared across dose levels to see whether each milligram of administered sildenafil produces broadly similar systemic exposure.
Under exact dose proportionality, dose-normalized AUC and Cmax should remain approximately stable. If normalized exposure rises systematically with dose, the data suggest greater-than-proportional behavior; if it falls, they suggest less-than-proportional behavior.
The small supra-proportional relationship observed across 25–200 mg means dose-normalized exposure would tend to rise modestly across that expanded range. Dose normalization is purely an analytical technique and should not be interpreted as a formula for changing a patient's dose.
| Dose-Normalized Pattern | Interpretation |
|---|---|
| Approximately stable AUC/dose | Consistent with proportional integrated exposure. |
| Increasing AUC/dose | Suggests greater-than-proportional AUC. |
| Approximately stable Cmax/dose | Consistent with proportional peak exposure. |
| Increasing Cmax/dose | Suggests greater-than-proportional peak exposure. |
A sildenafil dose-proportionality study requires multiple dose levels under comparable conditions so that exposure differences can be attributed as cleanly as possible to dose. One published analysis used an open-label randomized crossover design in 32 healthy male subjects receiving single oral sildenafil doses of 25, 50, 100 and 200 mg.
Serial plasma samples were used to construct concentration-time profiles and derive Cmax and AUC. Investigators then evaluated whether the relationship between dose and each PK measure matched exact proportional scaling.
Statistical testing detected nonproportionality over the complete 25–200 mg interval even though the numerical deviation was small. This illustrates why dose proportionality is a statistical PK question rather than simply observing that higher doses produce higher concentrations.
| Study Element | Sildenafil Research Example |
|---|---|
| Population | 32 healthy male subjects in the dedicated dose-proportionality study. |
| Design | Randomized crossover, single oral doses. |
| Dose levels | 25, 50, 100 and 200 mg. |
| Primary PK measures | AUC and Cmax. |
| Result | Small greater-than-proportional exposure across the complete 25–200 mg range. |
Pharmacokinetic variability makes proportionality harder to assess because different individuals can have substantially different sildenafil AUC and Cmax even at the same administered dose. A study therefore needs to distinguish a systematic dose trend from ordinary variability among observations.
Crossover designs can be useful because the same participants receive multiple dose levels, reducing some between-subject confounding. Statistical modeling can then estimate the average dose–exposure relationship while accounting for variability in measured concentrations.
A statistically detectable deviation does not automatically imply a large pharmacokinetic effect. In the 25–200 mg sildenafil study, nonproportionality was statistically evident but the numerical departure from exact doubling was relatively small. Broader sources of variability remain on the sildenafil PK variability page.
| Source | Possible Analytical Impact |
|---|---|
| Between-subject variability | Widens the exposure range observed at each dose. |
| Within-subject variability | Can change exposure even under repeated comparable conditions. |
| Sampling and analytical variability | Affects precision of AUC and Cmax estimates. |
| Systematic dose effect | Produces a reproducible exposure trend as dose changes. |
| Statistical significance | Does not by itself describe the magnitude of the departure from proportionality. |
Dose proportionality describes pharmacokinetic behavior, not the clinical suitability of a dose. The fact that exposure can be measured after 200 mg in a research study does not make 200 mg part of the current recommended ED dosing range.
Current U.S. ED labeling uses 100 mg as the maximum recommended dose and describes pharmacokinetics as dose-proportional over the recommended range. The 200 mg data are useful here only because they reveal what happens when PK research extends beyond that range.
Clinical dose selection involves indication, labeling, effectiveness, tolerability, interactions and individual assessment rather than extrapolating from an AUC-versus-dose curve. General regimen information remains on the sildenafil dosage page.
| Question | Domain |
|---|---|
| Does sildenafil exposure scale across 25–100 mg? | Pharmacokinetics; approximately dose-proportional in current labeling and population PK data. |
| What happened in a 200 mg research condition? | Exposure became slightly greater than proportional across the expanded range. |
| Is 200 mg a recommended ED dose? | No; it is outside the current maximum recommended ED dose. |
| Which dose is appropriate for an individual? | Clinical prescribing decision. |
The most accurate summary is range-specific. Current sildenafil labeling states that pharmacokinetics are dose-proportional over the recommended dose range, and population pharmacokinetic analysis supports proportional behavior over 25–100 mg.
When research extends the comparison to 200 mg, the relationship becomes slightly greater than proportional. In the dedicated single-dose study, doubling the dose was predicted to increase Cmax by about 2.2-fold and AUC by about 2.1-fold; the investigators characterized the degree of nonproportionality as small.
These findings are complementary rather than contradictory. Sildenafil behaves approximately proportionally across its recommended ED range, while data outside that range demonstrate why dose proportionality should never be extrapolated indefinitely. For the broader framework, the sildenafil exposure page and sildenafil pharmacokinetics hub connect dose with systemic input, concentration and elimination.
| Research Question | Sildenafil-Specific Interpretation |
|---|---|
| Is sildenafil PK dose-proportional in the recommended ED range? | Yes; current labeling states that it is. |
| What range is most relevant to that ED label statement? | 25–100 mg. |
| What happens when 200 mg is included? | Exposure becomes slightly greater than proportional across 25–200 mg. |
| How much did exposure rise for a twofold dose increase in that study? | Approximately 2.1-fold for AUC and 2.2-fold for Cmax. |
| Should the 200 mg research findings guide dose selection? | No. |
Current U.S. labeling states that sildenafil pharmacokinetics are dose-proportional over the recommended dose range. Population pharmacokinetic data also support dose proportionality over 25 to 100 mg.
Under exact dose proportionality, AUC would approximately double. In a research study spanning 25 to 200 mg, a twofold dose increase was predicted to produce about a 2.1-fold increase in sildenafil AUC, indicating a small greater-than-proportional relationship across that wider range.
Under exact proportionality, Cmax would approximately double. In the 25-to-200-mg single-dose study, a doubling in dose was predicted to increase Cmax by approximately 2.2-fold.
The statements refer to different ranges. Current labeling describes dose proportionality over the recommended dose range, while the research study extended the analysis to 200 mg, above the current maximum recommended ED dose, and found only a small greater-than-proportional deviation across that wider interval.
Yes. AUC measures integrated exposure while Cmax measures peak concentration. In the 25-to-200-mg sildenafil study, their estimated increases for a doubling of dose were approximately 2.1-fold and 2.2-fold, respectively.
No. Dose proportionality is a pharmacokinetic research concept. It describes how systemic exposure changes with studied dose and does not determine an appropriate individual regimen.